NCT01008696View on ClinicalTrials.gov

An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis

PHASE4CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Reflux Esophagitis
Interventions
DRUG

Rabeprazole

Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.

DRUG

Lansoprazole

Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01008696 - An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis | Biotech Hunter | Biotech Hunter